MedTrace Logo

14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy

NCT05191888 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 906

Last updated 2022-01-14

No results posted yet for this study

Summary

1. Test for Helicobacter pylori. The test items include urease test, histology, bacterial culture, serology, and urea breath test. At least two positive results can be used to confirm the diagnosis.
2. To ensure that the research results are not artificially distorted, this trial is a randomized study. Random allocation (which means that the subjects will use the "random number table generated by a computer similar to the lottery" to determine the treatment group) accept one of the following schemes (1:1:1).

Conditions

  • Helicobacter Pylori Eradication

Interventions

DRUG

Vonoprazan and Amoxicillin

14-day vonoprazan high-dose two-in-one therapy

DRUG

Vonoprazan, Amoxicillin and Clarithromycin

14-day vonoprazan triple therapy

DRUG

Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole

14th Rabeprazole reverse mixed therapy

Sponsors & Collaborators

  • Kaohsiung Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-06
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191888 on ClinicalTrials.gov